In the most recent analysis, the median progression-free survival was 29.7 months in the lanreotide-everolimus arm and 13.6 months in the everolimus-alone arm. The combination of lanreotide and ...

Findings from a recently presented study demonstrated that patients with unresectable or recurrent gastroenteropancreatic neuroendocrine tumors (GEP-NETs) may benefit from treatment with Afinitor ...

Cabometyx accounted for 17% of total product sales in the year and helped offset the hit from generic versions of Somatuline. We forecast steady revenue growth for Cabometyx, averaging about 10% ...

This treatment can help with symptoms caused by high hormone levels. It might also help control or shrink some NETs. Common somatostatin analogue drugs used are octreotide and lanreotide. Somatostatin ...

Michael McWhertor is a journalist with more than 17 years of experience covering video games, technology, movies, TV, and entertainment. So it stands to reason the animated intro may also provide ...

The hypnotic sequence, animated from three dimensional scans of Scott, became one of the series’ calling cards when it first premiered in early 2022 on Apple TV+. It earned Latta, a 3-D artist ...

Adding the somatostatin analog lanreotide to the mTOR inhibitor everolimus significantly prolonged progression-free survival in patients with unresectable or recurrent gastroenteropancreatic ...

Ipsen will be launching a new pre-filled syringe for its blockbuster rare disease drug Somatuline (lanreotide) in the EU. The new design was based on several studies, involving patients ...

To detect CDKN1C mutations or other gene mutations in the 11p15 region, genetic sequencing is performed. Briefly, PCR is performed to amplify the region of interest, then Sanger sequencing is used to ...

The term dilated cardiomyopathy (DCM) refers to a spectrum of heterogeneous myocardial disorders that are characterized by ventricular dilation and depressed myocardial performance in the absence of ...

Bristol-Myers Squibb has won FDA approval for the first LAG-3 inhibitor drug ahead of its rivals in cancer immunotherapy, including Merck & Co. The US regulator cleared BMS' LAG-3 drug relatlimab ...